

## SEASONED GLOBAL COMMERCIAL OPERATIONS EXECUTIVE DARLA HUTTON TO JOIN AROA'S BOARD, AND STEVEN ENGLE TO RETIRE

Aroa Biosurgery Limited is pleased to announce the appointment of Darla Hutton as an independent non-executive Director of the Company.

Based in the United States, Ms. Hutton brings over 25 years of international leadership expertise in life sciences commercial strategy, operations, sales, marketing and data analytics. She is currently Vice President of Commercial Operations and Marketing-Asia, at Silicon Valley-based Intuitive Surgical, Inc., the global leader in minimally invasive care. A member of the Nasdaq-100 and S&P 500, Intuitive is a pioneer in the field of robotic-assisted surgery and developed the da Vinci surgical robotic system. Its products are used in 70 countries and to date, in over 12 million procedures.

Ms. Hutton has held roles of increasing responsibility at Intuitive, including Vice President of Corporate Accounts-US and Vice President of Marketing, Market Access & Custom Hospital Analytics. She has contributed to the expansion of Intuitive's commercial operations, capabilities and range of global offerings. In addition to her core role, Ms. Hutton is also a member of the company's Diversity Council. Ms. Hutton has previously held commercial positions at global medical technology and pharmaceutical companies, including Boston Scientific and GlaxoSmithKline.

AROA CEO Brian Ward says: "With the breadth and depth of her experience, Darla will be a valuable addition to AROA's Board. In particular, her expertise in selling into the operating room is well aligned with AROA's focus on soft tissue reconstruction procedures. We look forward to having Darla on board."

Ms. Hutton's appointment will take effect from 22 March 2024, and she will stand for election at AROA's next Annual General Meeting.

The Company also announces the retirement of long-standing Director, Steven Engle, effective 31 March 2024.

AROA Board Chair Jim McLean says: "We are delighted to welcome Darla to AROA's Board of Directors. Her skills and expertise will help guide the Company's continued expansion in North America and beyond. On behalf of the Board, I would also like to thank Steve for his significant contribution. Over the past nine years, he has provided a wealth of knowledge to the Board and helped shape AROA's direction."

< ENDS >

**Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.**

### **About Aroa Biosurgery:**

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine forestomach. AROA has commercialised four product families based on its AROA ECM technology, targeting chronic wounds, hernia, soft tissue, and breast reconstruction. Over 6 million AROA products have been used globally in a range of

ASX ANNOUNCEMENT  
22 March 2024



procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. AROA has regulatory approvals in more than 50 countries. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX).

[www.aroa.com](http://www.aroa.com)

**Contact Details**

Sarah Tora

Corporate Communications Manager

+64 21 531043

[sarah.tora@aroabio.com](mailto:sarah.tora@aroabio.com)